ClinicalTrials.gg
RecruitingNCT06922084Updated Sep 30, 2026

A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects

A Phase 4 interventional study of Clareon PanOptix and Clareon PanOptix PRO in Cataract, sponsored by Berkeley Eye Center. Recruiting at 2 sites in United States. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Berkeley Eye Center · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Sep 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.

Planned enrollment
66th of 322
320 · median 100
Started
2025
with 23 others
Phase 4
86 of 456
7 open now
Primary completion
2027-04
later than 34 of 54 live
Registered
409th of 456
by date

Among the 456 studies in Cataract with a site in United States, this one is the 66th largest by planned enrollment of the 322 interventional ones that give a count, is one of 24 that started in 2025, is one of 86 in phase 4, reaches primary completion later than 34 of the 54 other live ones, and was the 409th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 456 studies in Cataract with a site in United States, or all of them as a file.
02

Study summary

Prospective, randomized, multicenter, multi-arm, subject and vision-assessor-masked, two stage study with Stage 1 as a three-arm initial enrollment period, followed by Stage 2 as a head-to-head study refined based on the Stage 1 data.

03

Conditions studied

  • Cataract

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult cataract patients aged 40 years and older scheduled for age related cataract surgery in both eyes.
  • Ability to understand and sign an ethics committee-approved form.
  • Willingness and ability to attend all scheduled study visits as required by the protocol.
  • Postoperative potential visual acuity of 20/25 or better in each eye, as determined by the investigator.
  • Preoperative corneal astigmatism that can be corrected with a T3 or T4 toric IOL, or with a spherical IOL and LRIs or AKs resulting in a predicted postoperative astigmatism of less than 0.5 diopters (D).
  • Ability to understand and complete questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, planning to become pregnant during the study, or breastfeeding.
  • Ocular conditions that could confound study results, including moderate to severe corneal pathology, irregular astigmatism, moderate to severe dry eye, preexisting retinal diseases such as macular degeneration or diabetic retinopathy.
  • Any form of confirmed glaucomatous damage (ie, mild, moderate, or severe glaucoma).
  • Participation in another clinical study that could interfere with the results.
  • Systemic conditions that may affect healing or visual outcomes (e.g., uncontrolled diabetes mellitus, certain disorders).
  • Subjects with nystagmus, strabismus, zonular laxity or dehiscence, and pseudoexfoliation.
  • Prior ocular surgery (except for uncomplicated cataract surgery in the fellow eye).
  • Participants desiring monovision.
  • Any active ocular infection or inflammation (except for routine post-operative inflammation in the fellow eye)
  • Psychiatric or cognitive disorders that may impair the ability to comply with study procedures or provide accurate self-assessments.
  • RMS total higher-order aberrations (HOAs) >0.70 µm or coma >0.40 µm as measured by tomography or topography with a 4 mm pupil setting.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
320 participants (estimated)

Study arms

  • Active comparator
    Bilateral Clareon PanOptix IOL implantation

    Device: Clareon PanOptix

  • Experimental
    Bilateral Clareon PanOptix Pro IOL implantation

    Drug: Clareon PanOptix PRO

  • Experimental
    Clareon PanOptix Pro in the non-dominant eye and Clareon Vivity in the dominant eye

    Drug: Mix-and-Match PanOptix/Vivity

Interventions

  • DeviceClareon PanOptix

    Bilateral Clareon PanOptix IOL implantation

  • DrugClareon PanOptix PRO

    Bilateral Clareon PanOptix PRO IOL implantation

  • DrugMix-and-Match PanOptix/Vivity

    Clareon PanOptix Pro in the non-dominant eye and Clareon Vivity in the dominant eye

06

What researchers measure

Primary outcomes

  1. Binocular photopic CDVA (corrected distance visual acuity)

    Time frame: 3 months postoperatively

Secondary outcomes

  1. Binocular photopic DCIVA (distance corrected intermediate visual acuity) and DCNVA (distance corrected near visual acuity)

    Time frame: 3 months postoperatively

  2. Binocular photopic uncorrected visual acuity at distance (UDVA), intermediate (UIVA), and near (UNVA)

    Time frame: 3 months postoperatively

  3. Binocular photopic small letter contrast sensitivity at 66 cm and 100 cm with refractive distance correction (20/32 line)

    Time frame: 3 months postoperatively

  4. Binocular mesopic high contrast distance corrected visual acuity at distance (CDVA), intermediate (DCIVA), and near (DCNVA).

    Time frame: 3 months postoperatively

  5. Binocular photopic distance corrected defocus curve

    Obtained by varying the vergence of the stimulus from -3.0 D to +1.0 D in steps of 0.5 D with the best correction for distance vision.

    Time frame: 3 months postoperatively

  6. Monocular photopic distance corrected defocus curves

    Obtained by varying the vergence of the stimulus from -3.0 D to +1.0 D in steps of 0.5 D with the best correction for distance vision.

    Time frame: 3 months postoperatively

  7. Binocular mesopic distance corrected contrast sensitivity with and without glare (1.5, 3, 6 & 12 cpd)

    Time frame: 3 months postoperatively

  8. Refractive outcomes

    Mean residual manifest refraction spherical equivalent (MRSE) and residual astigmatism.

    Time frame: 3 months postoperatively

  9. Pupil size

    Under both photopic and mesopic conditions.

    Time frame: 3 months postoperatively

  10. Patient-reported outcomes using a questionnaire about visual disturbances (QUVID)

    Time frame: 3 months postoperatively

  11. Patient-reported outcomes using a questionnaire about IOL satisfaction (IOLSAT)

    Time frame: 3 months postoperatively

07

Study locations

2 of 2 sites recruiting
  • Shafer Vision Institute
    Plymouth Meeting, Pennsylvania 19462, United States
    Recruiting
  • Berkeley Eye Center
    Houston, Texas 77027, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2027, 25 months after the start.

Of 39 non-industry phase 4 interventional studies under Cataract, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 25 months is above that.

Counting every sponsor, half of 46 studies reached it within 20 months; a quarter within 11 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Apr 2026 → Apr 2027 and completion Apr 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Apr 10, 2025
StartActual
Mar 17, 2025
Primary completionEst.
Apr 2027was Apr 2026
CompletionEst.
Apr 2027was Apr 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 2026→Apr 2027
Sep 30, 2026
Study completion
Apr 2026→Apr 2027
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Primary completion Apr 2026→Apr 2027
    Study completion Apr 2026→Apr 2027
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06922084
Lead sponsor
Berkeley Eye Center
Collaborators
Sengi
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
Mar 17, 2025
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Tetiana Huff
Contact
tetiana.huff@berkeleyeye.com
713-620-7640
Morgan Micheletti, MD
principal investigator · Berkeley Eye Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion